N
Nawel Bourayou
Researcher at Eli Lilly and Company
Publications - 20
Citations - 2119
Nawel Bourayou is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Fulvestrant & Cancer. The author has an hindex of 8, co-authored 15 publications receiving 1467 citations.
Papers
More filters
Journal ArticleDOI
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
George W. Sledge,Masakazu Toi,Patrick Neven,Joohyuk Sohn,Kenichi Inoue,Xavier Pivot,Olga Burdaeva,Meena Okera,Norikazu Masuda,Peter A. Kaufman,Han Koh,EM Grischke,Martin Frenzel,Yong Lin,Susana Barriga,Ian C. Smith,Nawel Bourayou,Antonio Llombart-Cussac +17 more
TL;DR: Abemaciclib at 150 mg twice daily plus fulvestrant was effective, significantly improving PFS and ORR and demonstrating a tolerable safety profile in women with hormone receptor-positive and human epidermal growth factor receptor 2-negative ABC who progressed while receiving ET.
Journal ArticleDOI
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz,Masakazu Toi,Mario Campone,Joohyuk Sohn,Shani Paluch-Shimon,Jens Huober,In Hae Park,Olivier Tredan,Shin-Cheh Chen,Luis Manso,Orit Freedman,Georgina Garnica Jaliffe,T. Forrester,Martin Frenzel,Susana Barriga,Ian C. Smith,Nawel Bourayou,Angelo Di Leo +17 more
TL;DR: Abemaciclib plus a nonsteroidal aromatase inhibitor was effective as initial therapy, significantly improving progression-free survival and objective response rate and demonstrating a tolerable safety profile in women with HR-positive, HER2-negative advanced breast cancer.
Journal ArticleDOI
Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): A phase II trial
Radj Gervais,Gilles Robinet,Christelle Clément-Duchêne,Fabrice Denis,Claude El Kouri,Philippe Martin,Nadia Chouaki,Nawel Bourayou,Jean-François Morère +8 more
TL;DR: The synergistic activity of pemetrexed with platinum agents in non-small cell lung cancer (NSCLC) and the renal safety of carboplatin suggest a balanced benefit/risk profile for this combination in elderly patients, and the ORR is within the range of data reported in the general NSCLC population.
Journal ArticleDOI
Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer
Rohit Lal,Gunnar Hillerdal,Riyaz Shah,B. Crosse,Joyce Thompson,Marianne Nicolson,Anders Vikström,Vanessa Potter,Carla Visseren-Grul,Maria J. Lorenzo,Yulia Dyachkova,Nawel Bourayou,Yvonne Summers +12 more
TL;DR: HD of pemetrexed maintenance treatment in patients with advanced nsqNSCLC was feasible, safe, and preferred by patients, while maintaining HRQoL and physicians were satisfied with distant patient management.
Journal ArticleDOI
MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy
George W. Sledge,Masakazu Toi,Patrick Neven,Joohyuk Sohn,Kenichi Inoue,Xavier Pivot,Olga Burdaeva,Meena Okera,Norikazu Masuda,Peter A. Kaufman,Han A. Koh,Eva-Maria Grischke,Martin Frenzel,Yong Lin,Susana Barriga,Ian C. Smith,Nawel Bourayou,Antonio Llombart-Cussac +17 more
TL;DR: Abemaciclib, an oral, selective inhibitor of CDK4 & 6, dosed on a continuous schedule, demonstrated clinical activity as monotherapy in patients with treatment refractory horm...